Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Up-front payment to be made to collaborator	$ 3,162.1	$ 2,965.1
Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to collaborating party			$ 900.0
Sanofi Collaboration Agreement, Immuno-oncology
Disaggregation of Revenue [Line Items]
Royalty payment to collaborating party, percentage of net product sales	11.00%
Sanofi Collaboration Agreement, Immuno-oncology | Regulatory Milestone | Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to collaborating party			100.0
Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestone One | Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to be made to collaborator			$ 65.0
Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestone Two | Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to be made to collaborator	$ 35.0
Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestones | Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to be made to collaborator	$ 100.0